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Summary 
The ability of a human coreceptor to function in mice was investigated by generating human 
CD4 (hCD4)-expressing transgenic mice on a mouse CD4-deficient (mCD4 -/-) background. 
From developing thymocyte to matured T  lymphocyte functions, hCD4 was  shown to be 
physiologically  active. By examining the expansion and deletion of specific V/3 T  cell families 
in mutated mice with and without hCD4, it was found that hCD4 can participate in positive 
and negative selection. Mature hCD4 single positive cells also were found in the periphery and 
they were shown to restore MHC class II-restricted alloreactive and antigen-specific T cell responses 
that were deficient in the mCD4 (-/-) mice. In addition, these hCD4 reconstituted mice can 
generate a secondary immunoglobulin G humoral response matching that of mCD4 wild-type 
mice. The fact that human CD4 is functional in mice and can be studied in the absence of murine 
CD4 should facilitate studies of human CD4 activity in general and human immunodeficiency 
virus 1 gp120-mediated pathogenesis in acquired immune deficiency syndrome specifically. 
oc//3 T cells are primarily subdivided on the basis of the CD4 
or CD8 coreceptors that they express. CD8 T cells recognize 
MHC dass I in conjunction with cytoplasmic peptide. Upon 
antigen recognition, these cells deliver effector function which 
leads to the killing of the cell that is recognized. In this way, 
these cytotoxic T cells play a major role to resistance to viral 
infection by the elimination of vitally infected cells. CD4 T 
cells recognize MHC dass II in conjunction with antigenic 
peptide that derives from the extraceUular compartment, or 
from intracellular vesicles. CD4 T cells either potentiate the 
inflammatory  response by the synthesis of the cytokines IFN-'y, 
TNF-c~ and/3, and so on, whereas a second subset of CD4 
T cells synthesizes the cytokines such as IL-4 and IL-5, and 
potentiates  the  humoral  immune  response  (1,  2).  The 
coreceptors CD4 and CD8 both interact directly with their 
ligands MHC dass I and II, respectively. Moreover, CD4 and 
CD8 interact directly with the tyrosine kinase kk via binding 
of this enzyme to the cytoplasmic tail of these molecules (3). 
In a way that is not well understood at present, this interac- 
tion contributes to the delivery of the antigen-specific  fig- 
nalling via the TCR-MHC interaction (4). 
CD4 and CD8 are also required for the development of 
T cells (Kaufman-Paterson,  K., L. C. Burkly, D. K. Kura- 
hara, A. Dunlop, D. Kioussis, C. Mamalaki, K. A. Flavell, 
and T. H. Finkel, manuscript submitted for publication; 5-8). 
Antibodies to these molecules block T cell development and 
recent studies using CD4 or CD8 deficient mice show defec- 
tive development of the helper and cytotoxic T cell compart- 
ments, respectively  (9,  10). Positive and negative selection 
of thymocytes was dysfunctional when a mutant class I mol- 
ecule that was unable to bind CD8 was used as a restriction 
element (5). Moreover, in mice that are deficient for mouse 
CD4, it has also been shown that the alloreactivity to MHC 
class II antigen and the antibody response to a T cell-depen- 
dent soluble antigen are markedly diminished (10). 
Despite having essentially identical functions in mice and 
humans, the overall homology of human CD4 (hCD4) 1 to 
murine CD4 (mCD4) is low (11). But upon closer inspec- 
tion, the amino acid sequence critical in binding to the src 
tyrosine kinase p56  lck is  100%  homologous. There is also 
functional evidence that human or mouse CD4 binds to the 
MHC II of the heterologous species (12-16)  although the 
mCD4-human MHC interaction is weaker than the corre- 
sponding heterologous hCD4-mouse MHC interaction in 
vitro (17-19). In fact, using different levels of surface hCD4 
1 Abbreviations  used  in  this paper:  hCD4, human CD4; mCD4, murine 
CD4. 
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have shown that the human coreceptor is functional in al- 
loreactive  responses. 
In light of these interspedfic  interactions intracellularly and 
extracellularly,  and the in vivo system available from mCD4 
mutants, we have tested whether hCD4 can reconstitute the 
cellular phenotype and function ofmCD4 at the organsimal 
level. We,  therefore, generated transgenic mice expressing 
hCD4 specifically in lymphocytes (H-/+),  and bred them 
onto mice homozygous for the disrupted CD4 gene (M-/-). 
To facilitate the analysis of T cell development and function, 
we also used mice transgenic for the chick OVA-specific TCR 
(O-/+). We show here that human CD4 can participate in 
negative and positive selection of T cells and reconstitute the 
mature T cell subsets in mice. This reconstitution also reestab- 
lishes function as illustrated by aUoreactive and antigen-specific 
responses as well as T cell-dependent B cell antibody responses. 
Materiah and Methods 
Transgenic  and Gene DisruptedMic~  The generation  of  the human 
CD4 transgenic line, 313, has been described in detail elsewhere 
(Kaufman-peterson, R., et al., manuscript submitted for publica- 
tion). Briefly,  the DNA construct for microinjection uses a 2.8-kb 
human CD4 eDNA fragment which is placed  in an artificially  pro- 
duced EcoRI site of the human CD2 promoter-locus control re- 
gion cassette (20, 21). This insertion also replaces the human CD2 
first exon and leaves the 5' flanking promoter and 3' flanking regu- 
lator sequences intact. The result is an expression that is construct 
copy number dependent and lymphocyte specific, independent of 
the position of integration in the mouse genome. The linearized 
construct was then injected into CBA/Ca  x C57BL/10 fertilized 
eggs in the standard manner (21). 
The mouse CD4-deficient line is described in Rahemtulla et al. 
(10). Mice homozygous for the disrupted gene (M -/-) were bred 
with the hCD4 transgenic mice. The latter mice used have been 
backcrossed to C57BL/6J seven times before the initiation of this 
breeding. Additional breeding and screening of the combined het- 
erozygous genotypes gave rise to mice that were H-/+ and M-/-, 
MHC haplotype b/b. 
The OVA-specific, MHC class II I-An-restricted TCR trans- 
genie line (O -/+) has been previously described (22) and was 
generously provided by Drs. Dennis I_oh and Kenneth Murphy 
(Washington University, St. Louis, MO). Briefly,  this TCR trans- 
genie construct incorporates  the productive  Vcz 13 and VB 8.2 chain 
genomic rearrangements that have  been cloned from the hybridoma 
cell line DOl1.10 (23, 24). These mice were similarly  crossed with 
the M -/-  mice and the progeny screened and bred to reach the 
O-/+M-/-  genotype.  One  such mouse  was  then  bred  with 
H-/+M -/-  females to create the O-/*H-/+M -/-  genotype and 
their respective transgene-negative  littermates  with the MHC haplo- 
type b/d.  We also bred the O+H-M -  mouse with B6 mice to 
generate O +  H-M-/+ mice to serve as controls in antigen-specific 
T cell activation and FACS  |  analysis (Becton Dickinson & Co., 
Mountain View, CA) experiments. As with the O§  - mice, 
these M § mice are heterozygous for CD4 and MHC class II al- 
leles (b/d). 
The transgenic 107.1 line is a mouse strain with wild-type ex- 
pression ofMHC II I-E generated initially on C57BL/10 mice and 
backcrossed onto the C57BL/6J strain (25). C57BL/6J, C57BL/10J, 
and CBA/ca/J mice  came  from The Jackson hboratory (Bar Harbor, 
ME). 
mAbs and Flow Cytometry.  For human PBMC staining, cells 
from venipunctures were recovered by centrifugation and RBCs 
lysed with a hypotonic 0.15 M ammonium chloride buffered solu- 
tion. The Leu3a FITC-cunjugated mAb (Becton Dickinson), was 
used in all staining for human CD4. Anti-CD8 Red6136TM-con  - 
jugated mAb came from Bethe'~la  Research  Laboratories  (Gaithers- 
burg, MD). For anti-CD3 staining, a PE-conjugated mAb, done 
145-2Cll  (Pharmingen, San Diego, CA), and FITC-conjugated 
KT3 (26), a gift from Howard Petrie (Yale University), were used. 
The biotinylated antibodies anti-B220 (clone RA3-6B2) and anti- 
Vfl5 (clone MKg-4) were also from Pharmingen. Anti-V~6 (done 
RR 4-7; Hybridoma Core Facility,  Yale University)  and anti-V~11, 
done RR 3-15, gift of  Ed Palmer (Basel Institute of Immunology, 
Basel, Switzerland) (27), were Ig purified from tissue culture su- 
pernatant by a protein G column and then biotinylated. Avidin-PE 
conjugated (Pharmingen) was used as a secondary reagent for the 
biotinylated antibodies. The mAb, KJ1-26, mouse IgG2a, was a 
gift from John Kappler (National Jewish Center for Immunology 
and Respiratory Medicine, Denver, CO) and is clonotypic for the 
OVA-specific TCK (28, 29). This antibody was used directly as 
tissue culture supematant. Secondary  antibodies, rabbit anti-mouse 
Fc FITC conjugate (A~ll, Westbury, NY) and goat anti-mouse 
PE  conjugate  (Southern Biotechnology Associates, Inc.,  Bir- 
mingham, AL) were used to recognize KJ1-26 before additional 
antibody steps were performed in muki-antibody staining experi- 
ments. For T cell enrichment, 212.A1, a anti-I-A  b,~ mAb (30) ac- 
quired from the Yale Immunobiology Hybridoma Core Facility, 
was used at 1.4/~g/ml/107 cells (see T cell enrichment below). 
Cell preparation for FACS* analysis  and T cell enrichment were 
performed  by gently mashing  spleens  and LNs  between  nylon screens 
to homogenize, and the cells were then washed in HBSS 2.5% 
FCS. RBCs were lysed with a buffered 0.15 M ammonium chlo- 
ride solution. The remaining nucleated cells were then incubated 
with the various aforementioned antibodies in saturating concen- 
trations at 1-5  x  10' cells/0.1 ml of staining buffer (PBS with 
5% FCS and 0.1% sodium azide) for 30 rain on ice and washed 
twice before the next antibody step. Samples  were analyzed  by flow 
cytometry using the FACStar  Plus* flow cytometer (Becton Dick- 
inson & Co.). Plotting and analysis  of  the collected  events  was done 
using the LYSYS II software program (Becton Dickinson & Co.). 
T  Cell Enrichment.  Freshly harvested spleens and LNs were 
treated as for cell preparations for FACS* analysis. 100  x  10" cells 
were incubated with the mouse mAb 212.A1 for 60 min at 4~ 
After washing in HBSS 2.5% FCS, cells  were resuspended  in flasks 
containing goat anti-mouse Ig antibody coupled to magnetic beads 
(Collaborative Biomedical Research, Bedford, MA). After a 45- 
min incubation with gentle rocking, a magnet was applied to re- 
move the 212.A1 bound and surface Ig cells that had taken up the 
goat anti-mouse antibody/magnetic  beads. This whole cycle  of  mag- 
netic beads coupled to antibody incubation and magnet removal 
of  cells with class II MHC and surface Ig was repeated. The field 
was consistently  between 88 and 95% CD3 § cells with <5% con- 
taminating cells B220  §  This method of T cell enrichment was 
used in all the MLR and antigen-specific  proliferation assays and 
in preparing cells for V~ staining to examine  positive and negative 
selection. 
MLR and Antigen-specific Proliferation  Assays.  Immediately  after 
the T cell enrichment procedure, serial dilutions of the cells were 
done and plated in quadruplicates  in round-bottomed 96-well phtes 
(Costar Corp., Cambridge,  MA) in Brufl~s-gentamicin  medium sup- 
plemented with 5%  FCS (Hyclone Laboratories, Logan, UT). 
Stimulator  calls  for MLP, assays  were B6 or transgenic 107.1 spleno- 
cytes, irradiated with Cs 139 (2,500 tad), at 5 x  10  s cells/well. For 
1234  Human  CD4 Repladng Murine CD4 in Mice antigen-specific proliferation, irradiated self-splenocytes  were used 
and chick OVA (Sigma Chemical Co., St. Louis, MO) was added 
to reach a final volume of 0.2 ml/well. Assays of alloreactivity were 
allowed to go 5 d  with a  16-h  [~H]thymidine pulse at the end. 
Antigen-specific proliferation went 72 h and pulsed for the same 
duration. Wells were harvested onto paper filters with a cell har- 
vesting system, and counted in a beta counter (Betaplate 1502; 
WaUac, Gaithersburg,  MD). 
ELISA.  3-4-mo-old mice of the H-M-, H*M-, B6, H+M § 
background  were  immunized  with  50  #g  KLH  (Calbiochem- 
Novabiochem Corp., San Diego, CA) in CFA intraperitoneally. 
A booster in IFA was given at 3 wk and serum collectr  at day 
10 and week 5. KLH (20/~g/ml) in PBS was allowed to coat poly- 
vinyl chloride 96-wall plates overnight at 4~  The phtes were 
washed in borate saline, blocked with 1% BSA, and incubated with 
increasing dilutions of serum for 2 h at 21~  After washing, goat 
anti-mouse total IgG (H +  L) horseradish peroxidase-conjugated 
antibody (Bethesda Research Laboratories) was applied for I  h at 
21~  A 4-aminoantipyrine/phenol/HzOz solution was then used 
as a substrate.  Calorimetric readings using a spectrophotometer 
(Titertek Multiscan;  Flow Laboratories-ICN, Costa Mesa, CA) were 
taken at 20-min intervals. 
Re.ul= 
Expression of Human CD4 in Mice.  Before assessing how 
hCD4 may substitute for the function of mCD4, we deter- 
mined  the  level and  distribution  of hCD4  expression.  As 
predicted  by previous  works  using  the  same human  CD2 
promoter-regulator (Kaufraan-Paterson et al., manuscript sub- 
mitted for publication, and 20, 21), this transgene is expressed 
in nearly all lymphocytes. Consistently, >95% of the T cells 
in  our  transgenic  mice  are  hCD4 §  When  further  sub- 
divided, >95% of CD8 and 99%  of mCD4 + cells coexpress 
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Figure  1.  (A-D) Two-color staining of LN cells. Although  the per- 
centage of cells in each lymphocyte subset varies depending on the trans- 
genic mouse line, the percentage of CDS, mCD4, and B cells that are 
hCD4* in these profiles is representative and consistent within and be- 
tween different mouse lines. 
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Figure 2.  (A) FACS  ~ analysis of surface hCD4 expression. The expres- 
sion of hCD4 in human PBMC is approximately five times higher in rela- 
tive mean intensity than the different hCD4 (H*) transgeaic lines. A 
minority of the cells in the M- lines expresses a higher amount of hCD4. 
When gated for the CD3 +  CD8- (B) population, they remain. (C) This 
subpopulation disappears in the CD3 +  CD8 + gated cells indicating that 
the higher expressing cells are hCD4 single positive T cells. The trans- 
genic specimens  used for staining came from LN and in the human PBMC 
profile, gating was done on the lymphocyte fraction by forward and side 
scatters. 
hCD4 (Fig.  1, A  and B). Consistent with the fact that mu- 
fine CD2 is also expressed in some B cells, we find that hCD4 
directed by the human CD2 promoter is present in about 
70-80%  of the B cells (Fig.  1,  C  and D). This pattern of 
expression is maintained in the three lines of mice that carry 
the transgene, i.e.,  transgenic line 313 expressing both rou- 
tine and human CD4 (H +  M +), mice that have the human 
CD4 transgene on a background that is homozygous deficient 
for routine CD4 (H + M-),  and finally,  the latter mice also 
carrying a TCK transgene specific for OVA (O) in the con- 
text of bA  d (O +  H +  M- ). Hence, the presence of the OVA- 
TCR transgene or the absence of the mCD4 gene product 
does not affect the distribution or the expression of hCD4. 
The level of hCD4 is similar in mCD4 and CD8 positive 
T  cells.  It is interestingly to note, however, that hCD4 is 
expressed at a higher level in a minority of single positive 
T cells that lack mCD4 (CD3+hCD4+CDS-)  when com- 
pared (Fig.  2, A-C and see below). 
Finally, we also compared the expression level of the trans- 
1235  Law et al. gene to its natural endogenous counterpart in human PBMC. 
Fig. 2 A  shows that surface hCD4 expression is at least five 
times higher in human cells than in transgenic mouse cells. 
Reconstitution of the T-lymphocyte Subsets.  As reported by 
Rahemtnlla (10), 90% of the T cells in the periphery of the 
M- mice are CD8 + and 10% are CD3+CD4-CD8 - . This 
disproportionate shift of single positive cells to the CD8 + 
phenotype is corrected by hCD4. Fig. 3 shows the reconsti- 
tution of hCD4 single positive ceils.  In the H+M -  mice, 
the  CD3 §  ceils  are  composed  of 56%  CD8 +  cells  and 
>40% hCD4 single positive ceils (Fig.  3 A). Human CD4, 
therefore, permits approximately fourfold more T calls to be 
selected for MHC class II recognition. As we will show below, 
these hCD4 § T  cells are also functional in T  cell assays. To 
confirm this observation and because B cdl contamination 
can increase the apparent number of hCD4 +  CD8- cells, we 
performed three-color staining using anti-CD8,  B220, and 
hCD4 antibodies with gating on the CD8-/B220-  popu- 
lation;  this  showed the  same percentage  of hCD4 +  cells 
(data not shown). The rescue ofCD4 T cells by hCD4 trans- 
gene expression is still greater in the TCR transgenic mice. 
Most CD3 + cells (>70%) are hCD4-CD8-,  and 25% are 
CD3+CD8 + in the O+H+M -  mice, as shown by Fig. 3 B. 
Likewise, in the OVA-TCR transgenic with mCD4, the per- 
centage of CD4 cells is even higher,  reaching  82%  of all 
CD3 + cells (Fig. 3 C). It is also to be noted that the gross 
appearance of the thymus, LNs, and spleen was normal in 
these various lines of transgenic and/or mutated mice. The 
total number of ceils in the spleen and its absolute number 
of T  cells  (CD3 +)  and  B  calls  (B220 +)  was  not  altered 
significantly as compared with B6 mice of a similar age (data 
not  shown). 
Human CD4 Redirects Positive and Negative Selection.  To 
examine whether positive and negative selection ensues from 
the interaction  between immature  thymocytes and thymic 
epithelium (MHC II +) when hCD4 is expressed in place of 
mCD4, we studied the Vfl profiles of littermates  (O-M- 
and either H-  or H +) from the H +  M -  (MHC I-A + I-E-) 
and O+H-M -  (I-A+I-E +) cross. 
To compare the quantitative effectiveness of hCD4 in posi- 
five and negative selection in mice that are defident in mCD4, 
we  focused  specifically  on  the  mature  peripheral  CD3 + 
CD8-  subset.  In  mice expressing human  or mouse CD4 
coreceptors,  these  cells  are  all  CD3+CD4 +.  In  the 
O-H-M-  mice, however, these cells (CD3+CD4-CD8 -) 
had  no  coreceptors  and  consisted only of 10-15%  of the 
CD3 + ceils. They were compared with the CD3 +  HCD4 + 
CD3 -  cells of the O - H +  M -  mice. In the O- H +  M -  mice, 
this is the hCD4 single positive subset which increased to 
40-45%  of the CD3 + cells.  Additionally,  we used mCD4 
single positive calls  from B6 mice (I=E  b negative)  and B6 
mice  expressing  an  I-E  transgene  (transgenic  line  107.1, 
I=E +) as controls. 
Vfl6 + CD4 T  cells are positively selected by I=E and as 
a result show an elevated percentage in I=E + mouse strains 
(31).  V~/6 + CD4 ceils (see Fig. 5 B) account for 7.85% in 
B6 mice that lack the I-E selecting dement but increase to 
11.45%  of the  CD3+mCD4 +  subpopulation  in  the  syn- 
geneic I-E + 107.1 mice. This number falls to 7.79% in the 
O-H-M-  mice lacking CD4 (the same level seen without 
I-E in the control B6 mice), despite the presence of I-E. HCD4 
reconstitutes  this  V~6  population  to  10.35%  in  the 
O-H+M -  mice, showing that as determined by this assay, 
hCD4 can function equally well in positive selection as the 
endogenous  murine  CD4 gene. 
We also examined the positive selection of OVA-TCR cells 
in the mCD4=defident background. The selection of the OVA- 
TCR clonotype does not absolutely require CD4. Thus, in 
the CD8-  subset (which is also CD4-)  of the O+H-M - 
mice which comprises 10-15% of the CD3 + calls, 52% ex- 
press the OVA-TCR donotype (Fig.  4 C). Of the 85-90% 
of the remaining CD3 + cells that are CD4- CD +, 50% are 
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Figure 3.  The distribution of CD4 vs CD8 cells 
in different lines of trans~enic and or mutated mice 
is demonstrated by FACS  ~ analysis of the staining for 
CD8 in the CD3 + gated population. The relative cell 
number is in the vertical axis. The percentage of ceils 
within the region bar is the CD4 single positive sub- 
popuhtion in CD4 expressing mice (A-C) because 
within this subpopulation, ;>97% of the cells  are hCD4 
or mCD4 positive (data not shown). (D and E) This 
CD8- subpopuhtion is also CD4- and occupies only 
12-15%  of the T lymphocyte compartment but, is 
largely restored in the hCD4 mice. Samples used for 
staining came from LN and spleen and enriched for 
the T cell fraction. Three-color staining was then per- 
formed using combinations of conjugated antibodies 
as  described in Materials and Methods.  The  total 
number of ceils in the spleen as well as the absolute 
numbers oft and B ceils in this organ were not found 
to be significantly different among these mouse lines. 
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Figure 4.  The selection for the MHC class ll- 
restricted OVA TCIL cells in various experimental 
mouse lines  is  ilustrated  in  these profiles of 
CD3+CD8 -  gated cells and their staining by KJ1- 
26, the clonotype-specific  antibody.  In mice  with CD4 
(.4, B, and D),  the gated cells are essentially all 
CD4 +. In the O+H-M -  line (C), the gated cells 
lack coreceptors. In the presence of human  or mouse 
CD4 and OVA TCR (+4 and B), the percentage of 
clonotype-sdected  cells increased  above the level seen 
in the O+H-M - line consistently,  and the profiles 
shown are representative  of a minimum  of five mice 
from each line studied. 
clonotypic (data not shown). However, the presence  of ei- 
ther human or mouse CD4 not only increases the size of 
the CD3+CD8 -  subset itself but also  that of the CD8- 
subpopulation (which is CD4 +) which is donotypic. For 
example, the percentage of CD4 single positive cells increased 
from '~60%  (data not shown) to 82%  in the O+H-M + 
mice (Fig. 3 C), and from 44% (O-M+M -) to 75% in the 
O+H+M -  mice (Fig.  3, A  and B).  Furthermore, within 
this CD8 negative or CD4 single positive population, >70 
and 80% (vs 52% in mice lacking CD4) are clonotypic in 
the O +  H- M + and O +  H +  M -  mice, respectively (Fig. 4, A 
and B). 
VB5 and Vi~11 T  cells are ddeted in mice that express a 
functional I-E molecule in conjunction with the endogenous 
retroviruses MMTV (mouse mammary tumor virus) 6,  8, 
and 9  (32,  33).  To address  whether hCD4 can participate 
in and influence negative selection,  we therefore determined 
the percentage of V/35 and VBll  T  cells in the periphery 
(Fig. 5, D and F). The percentage of V/~5/CD8-  or CD4 + 
and VBll/CD8-  or CD4 + cells in I-E +  107.1 transgenic 
mice was 0.64 and 0.39%, respectively,  in the presence  of 
mCD4. In the O-H +  M- mice, hCD4 maintains this dele- 
tion at 0.75% (V~5) and 1.5% (VBll). In the O-H-M- 
mice,  we used the CD3+CD4-CD8 -  population as  the 
corresponding subset to compare with the mouse or human 
CD4 single positive subset. For VBS, it consisted of 2.12%, 
and for Vl~11, 3.56%  of the double negative peripheral T 
cells despite the presence  of I-E.  In the absence of I-E but 
in the presence of mCD4 as in the B6 mouse strain (which 
is syngeneic to strain 107.1), it is 3.58 and 4.98% for Vl~5 
and V~11,  respectively.  The intermediate level seen in the 
O-H-M-  mice suggests that although CD4 enhances the 
negative selection of these V~ families in the presence of I-E, 
it is not mandatory. It is possible that the affinity of the in- 
teraction between some VB TCRs and their class II ligand 
is such that coreceptor assistance is not necessary in the dele- 
tion process.  It is interesting to note that consistent with 
this observation, deletion of  both V1311 and more strikingly, 
VI~5, also occurs in the CD8 T cells of mice without human 
and mouse CD4 (O-H-M-).  The deletion of these cells 
was thought to be due to the interaction of CD4 with MHC 
class II during the double positive stage of the thymocyte 
development (34,  35).  It is 3.05% for VB5 and 4.57% for 
VBll, a level significantly lowe~ than that seen in the B6 strain 
(12.55 and 7.15%, respectively),  and nearly matches the per- 
centages seen in the transgenic 107.1 and O-H § M- strains 
(Fig. 5, C and E). This finding again suggests that there is 
not an absolute requirement for CD4 for the recognition of 
superantigen during T  cell development. 
Human CD4 Participates in Alloreactivity and Antigen-specific 
Response.  In attempting to define the role of hCD4 in the 
mouse T cell response, we first set up a primary mixed lym- 
phocyte response disparate in a single MHC class II I-E an- 
tigen. This was achieved by using the I-E~  a transgenic 107.1 
line bred onto the B6 background. Serially diluted responder 
cells from 88-95% T cell-enriched preparations were set up 
with irradiated stimulator cells provided by 107.1 or B6 spleno- 
cytes  (Fig.  6).  The  responsiveness  of  the  H+M -  cells 
matched that of the T cells from the B6 and transgenic 313 
line (H+M+), whereas that of the H-M-  cells is markedly 
diminished. Similarly,  Killeen et al. (36) also showed resto- 
ration of alloreactivity to an MHC class II antigen (H-2  bm12) 
when a human CD4 transgene was expressed in a different 
mouse CD4-deficient line (see Discussion). 
Since  CD4  should  also  potentiate T  cell  activation to 
processed  soluble antigen presented by MHC II molecules, 
we used the O +  H +  M- mice to test whether T cell prolifer- 
ation to antigen is restored. When irradiated splenocytes were 
1237  Law et al. 14" 
13" 
12' 
(/1  11" 
10' 
9 
O  8 
e,-  7- 
~.  5- 
4- 
3 2 
2 
16- 
1 si 
14- 
1 3' 
__.~  1 2 ~ 
"~  11-' 
(J  1 0" 
9' 
O  8-' 
7- 
c:  6' 
5- 
~  4:  ~  . 
3" 
2" 
0' 
10- 
9" 
8' 
4,1  7' 
U 
6"  q.,, 
o 
5. 
4,,a 
r,,.  4. 
~  3' 
~,. 
Figure  5. 
A 
C 
E 
Vbeta  6/CD8 
N:8  ￿9 
M=6.08 
S=1.85  l  e  ￿9 
[]B D 
[]  N=9 
B  M=8.73 
S=0.47  [] 
Positive 
N:12 
M:9.74 
S=0.36 
§ 
§247 
*t § 
o 
o 
080 
o  o 
o 
o  o 
o 
N=12 
M=10.75 
S=0.89 
14- 
13- 
12- 
(/1  ' 
~  11- 
U  ￿9 
10- 
O  9- 
~  8-  (1) 
R  ￿9  7- 
D.. 
6- 
5- 
B 
N=8 
M=7.85 
S=1.21 
m 
[] 
rl 
B 
!  !  i  ! 
B6  TG  107.1  O-H-M-  O-H+M-  4 
Vbeta  5/CD8  Positive 
6.0- 
B  5.5 
[]  5.0 
[]  4.5  (/I 
[] 
4.0  LJ 
[]  3.5 
,4- 
N=6  O  3.0 
M=  12.55 
S=2.37  N=11  4~  ?. 5 
M:3.05  r" 
S:0.77  Q) 
N=7  ~g.  2.0 
M=2.21  +  +  N=10  ~1  1.5 
S=0.37  +  +  M=1.48  r~ 
,  ~ §  s.03,  1  o 
:I"  +  0.5 
,  ,  ,  ,  0.0  , 
B6  TG 107.1  O-H-M-  O-H+M-  B6 
Vbeta  11/CD8  Positive 
[] 
[]  N=11 
[] [] []  M=4.57 
S=0.81 
+ 
[]  +§ 
N=7 
N=6  M=3.11  +  +§ 
M=7.15  S=0.65 
S=1.07  + -1: 
t 
o  ++ 
Vbeta  6/CD8  Negative* 
r 
L) 
q- 
O 
r" 
R  q) 
ete 
N=11 
M=7.79 
S=.1.24 
§ 
N=9  + 
M=11.45  + 
S=0.79 
§ 
+ 
N:9 
M=2.68 
S:0.63 
D 
oo 
o~o 
o 
i  i  ! 
B6  TG 107.1  O-H-M- * 
Vbeta  5/CD8  Negative* 
o 
08 
oo 
o 
8 
o 
N-11 
M=10.35 
S=1.17 
W 
[] 
N=6 
M=3.58 
S=0.97  N:7 
M=0.64 
S=0.11 
"|: 
i 
TG 107.1 
! 
O-H+M- 
N=11 
M=2.12 
S=0.83 
§ 
§ 
§ 
I 
O-H-M-* 
F 
Vbeta  11/CD8  Negative* 
6.0. 
m 
[] 
[] 
[] 
[]• 
N=6 
M=4.98 
S=0.51 
N=7 
M=0.39 
S=0.11 
ooo 
eeoo 
i 
TG 107.1 
5.5" 
5.0 ￿9 
4.5. 
4.0 ￿9 
3.5 ￿9 
3.0' 
2.5' 
2.0 i 
1.5- 
1.0 ~ 
o.s 2 
4-+ 
+§ 
+ 
$ 
$ 
N=9 
M=3.$6 
S=0.85 
N:10 
M=0.75 
S:0.22 
8 
o~~ 
! 
O-H+M- 
N=7 
M=1.50 
S=0.17 
~ 
'  '  '  '  0.0  ,  ,  , 
B0  TG 107.1  O-H-M-  O-H+M-  B6  O-H-M-  *  O-H+M- 
These graphs depict the percentages of V~ lymphocytes analyzed within the T  cell subsets. In the B6, TG 107.1 and O-H-M-  mouse 
lines, the CD8 + subset (.4, C, and E) is of the CD3 +  CD8 + phenotype. In the O- H +  M -  line, the CD8 subset is of the CD3 +  CD8 +  hCD4 + pheno- 
type. For the CD4 or CD8- subset (B, D, and F) in the B6 and TG 107.1 lines, this consists of the CD3+CD8 -  mCD4 + population. In the O-H*M - 
line, this consists of the CD3 +  CD8 - hCD4 + population and in the O- H- M-  line, this consists of the CD3 +  CDS- CD4-  population (*). Three- 
color staining was done using the designated anti-VB antibodies, anti-CD3,  and anti-CD8 on T  enriched cells.  The CD3 +  CD8-  cells were further 
1238  Human CD4 Replacing Murine CD4 in Mice O 
T- 
E  D. 
O 
t" 
i 
t- 
.9 
O 
O 
O  _c 
.c_ 
_ 
E  >,, 
e- 
l'- 
z, 
60 
50 
40 
30 
20 
10 
0 
.01 
MHC  CLASS  II  DISPARATE  MLR 
,t 
s S 
,~  .---.--a--- 
II  1  3. 
III 
III  ￿9 
I I  ss  ~I  ._.~__ 
'S;,i  z_-  Z- 
# 
t--.-'Ir..  =...~  ..... 
.1  1 
6 
T  Enriched  Responders  x  10 
fed OVA and incubated with T-enriched unprimed cells from 
either  O-H-M  +,  O§  +  (product  of the B6/O+M - 
cross),  O+H+M -  or O+H-M  -  mice,  there  was  again  a 
marked  enhancement  of proliferation  in  the  OVA-TCR 
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of cells were incubated with increasing amounts of antigen, 
a similar pattern of difference in responsiveness was also seen 
(data not  shown). 
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Figure  7.  The response  of  various OVA TCIL transgenic lines to OVA. 
The response of serially diluted unprimed T-enriched cells to OVA was 
assessed by proliferation or thymidine incorporation after incubation with 
irradiated O- syngeneic splenocytes and 100 #g/ml of antigen for 3 d. 
Cells were incubated in triplicate wells and the data shown here is repre- 
sentative of  three other experiments using additional mice. When the con- 
eent-radon of  antigen was serially diluted and the stimulators and responders 
were kept constant, a similar pattern and difference in response was seen. 
B6 vs Self 
TG313 (H+M+) vs Serf 
H-M- vs Serf 
H+M- vs Serf 
86 vs TG 107.1 
TC-,313 (H+M+) vs TG107.1 
H-M- vs TG107.1 
H+M- vs TG107.1 
Figure  6.  An MHC class II disparate primary MLK using 
T-enriched cells from mice with or without  human CD4 
and/or mouse  CD4. Experiment shown  here was done in tripli- 
cate wells and is representative of  two other experiments done 
using additional mice. See Materials and Methods for ex- 
perimental details. 
interaction,  mice were  immunized  with  KLH,  a  T  cell- 
dependent antigen, boosted, and the secondary antibody re- 
sponse analyzed by an antibody capture ELISA (Fig. 8). Al- 
though the mice without CD4 still mounted a modest re- 
sponse,  the  control  B6  and  experimental  H+M -  mice 
produced a specific IgG response at least three times larger. 
Another experiment using two mice from each group and 
including the 313 transgenic line (H+M+), produced similar 
results with the 313 response matching that of the B6 and 
H *M-  mice (data not shown). These observations are con- 
sistent with studies of Killeen et al.  (36), who showed that 
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Figure 8.  An antibody capture ELISA  was performed to measure the 
specific total serum IgG titer 5 wk after the primary immunization. The 
values are from the means of three mice from each group. Another experi- 
ment using two mice from each group showed a similar difference be- 
tween the H-M- and the H+M - mice and, with the B6 response equiva- 
lent to the H +  M- response. 
checked for mCD4 or hCD4 expression by separately staining for these three markers. CD4 expression was seen in >97% of these cells in all the 
experiments performed. B6 is I-E- and the other three mouse lines are I-E +  . Each symbol plotted represents a single mouse analyzed. (N) Number 
of mice analyzed; (M) mean; (S) standard error of the mean. 
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in CD4-deficient mice carrying the human CD4 transgene. 
Discussion 
In this paper we present evidence that the human T  cell 
coreceptor, hCD4, is functional in T  cell development and 
T cell function in mice. In mice that are deficient in mCD4, 
CD8 + lymphocytes occupy 90%  of the peripheral  T  cell 
compartment. The expression of hCD4 in these mice restores 
the CD4  single positive population  to 40-45%,  facilitates 
positive and negative selection in the thymus, and hCD4 func- 
tions in T  cell activation in vitro and T  cell help in vivo. 
Using a mCD4  enhancer  and the human  CD4 promoter, 
Killeen et al. (36) recently observed a restoration of 70% when 
hCD4 is expressed as a transgene in mCD4-deficient mice. 
The larger percentage (70 vs 40--45%) of restored single posi- 
tive CD4 T  cells in the latter system is most likely due to 
the higher expression level of hCD4.  Despite the fact that 
the expression level is somewhat lower in our system, func- 
tional reconstitution  is obtained. 
To establish functionality of hCD4 in our mouse system, 
we first looked at thymic selection.  HDC4 participates  in 
negative sdection of V35 and VEll cells that are deleted in 
the context of MHC II I-E and "self  ~' superantigen.  This 
process is defective in the H-M-  thymus, but is restored for 
the CD4 lymphocytes of the V35 and Vflll families in the 
H  + M-  mice, since the percentages of these V/3 clones in the 
periphery  of the  reconstituted  mice  (O-H+M -)  nearly 
match those of the I-E-expressing M + transgenic mice (line 
107.1). In addition, this effect carries over to the CD8 subset 
because hCD4  is  also  present  in  the  CD8 +  cells  in  the 
O-H +  M- transgenic mice which causes a further deletion 
of the  CD8 + V/35  and V311 cells.  Moreover,  deletion  of 
CD8 + V/35 and V/311 T  cells also occurs to some extent in 
the H-M-  thymus despite the absence of CD4. Previously 
it was considered that the deletion of these CD8 T  ceils by 
MHC class II presented superantigen occurred at the double 
positive CD4+CD8 + stage and was therefore mediated by 
CD4 (34,  35).  Our finding  here confirms the observation 
of Wallace et al. (37) who also examined the negative selec- 
tion of CD8 cells with other strains of mice and different 
V3 families.  That is, it is possible that CD4 may not be ab- 
solutely necessary for deletion of some V/3 groups. Alterna- 
tively, this deletion can occur at a stage other than the double 
positive cell stage at which CD4 can exert an effect. Hence, 
negative selection of certain V3 families may not absolutely 
require CD4 but it is enhanced in the presence of CD4. For 
positive selection, we examined V/~6 T cells selected by I-E, 
and  the  OVA-specific TCR  transgenic  T  cells  selected by 
I-A  a. Again, we observed the percentage of V~6 CD4 cells 
in the O-H+M -  mice (10.35%) to be above the I-E-  B6 
control (7.85%), and equivalent to the 1-E-expressing trans- 
genic 107.1 control (11.45%). The OVA-specific T cells are 
strongly positively selected in hCD4-expressing mice com- 
prising •82%  of peripheral hCD4 single positive T cells in 
O+H+M -  mice, vs. a similarly large 73% in the O+H-M + 
mice. The reason why a slightly higher percentage is actually 
seen in the O +H+M-  mice is not  clear. 
Recent work (Kaufman-Paterson  et al., manuscript  sub- 
mitred for publication, and 38, 39) using transgenic and gene- 
deficient  mice  has  provided  new evidence supporting  the 
stochastic model of positive selection. According to this model 
(40, 41), a developing T  cell with a TCtL that is class II re- 
stricted goes through a stage where either CD8 or CD4 is 
randomly turned off. At this intermediate  stage, ff CD4 is 
present and the TCK engages its cognate dass II ligand, then 
this cell will have been successfully sdected for maturation. 
Since hCD4 is constitutively expressed in the CD8 + ceils in 
our transgenic mice, we have asked whether this affects the 
unusually large percentage of CD8 calls that proceeds through 
positive selection. For example, hCD4 may not only rescue 
the CD3+CD8 -  MHC class II-restricted T cell population 
but  also  those cells  that  are CD3+CD8 + that  would not 
have been selected. 
In the V~ sdection of our O-H+M -  mice that are I-E + 
and have CD4 on CD8 + cells,  small effects  on the CD8 + 
subset can be observed. First, the percentage of V/35 and Vflll 
CD8 + cells from these mice is lower than that in the trans- 
genie 107.1 mice (Fig. 5, C and E), suggesting that negative 
selection in this population has been aided by the presence 
of hCD4.  Similarly,  the percentage of Vfl6 CD8 + cells is 
slightly  higher  in  the  O-H+M -  than  in  the  transgenic 
107.1  mice (Fig.  5 A).  The  small increase of V/36  CD8 + 
cells  in  the O-H+M -  mice could suggest  a rescue effect 
provided by hCD4 and hence be consistent with the stochastic 
model of positive selection. To directly assess whether the 
CD4+CD8 + cells were selected by MHC class II and to test 
the stochastic model functionally, we can take advantage of 
our transgenic/mutated  mouse system by sorting for OVA- 
TCK+CD4+CD8 +  ceils  and  compare  their  response  to 
OVA with OVA-TCR + human or mouse CD4 single posi- 
tive cells.  This work is in progress. 
Finally,  we have also provided evidence that  the restora- 
tion of the CD4 single positive phenotype is functional at 
the level of the mature T  cell.  That  is,  cells from H+M - 
mice respond  markedly better  to  allo-MHC  class  II  than 
H-M-  cells  in a primary class II disparate MLR and,  re- 
spond better in an antigen-specific manner when the OVA- 
TCR mice are used. Both responses dosely match that  of 
the mCD4 wild type. In addition, T  cell hdp is restored in 
H  + M-  mice since good levels of antibodies to KLH are ob- 
tained after immunization in both primary (36) and secondary 
antibody responses as shown in our  study. 
Mice with targeted disruptions of a given gene should not 
only allow the exploration of the function of the defective 
gene, but should also make possible refined animal modds 
to study human physiology or disease.  There is strong evi- 
dence to suggest the CD4 cell dysfunction and perhaps loss 
in HIV-1 infection is in part due to indirect mechanisms medi- 
ated by Env gpl20-CD4 interactions  (42-46).  Certain  an- 
toimmune diseases may also involve the interaction between 
CD4 and predisposing HLA ligands. Since human CD4 is 
functional in transgenic mice, mice that express a physiolog- 
ically active human  CD4 replacing its murine counterpart 
may provide a useful model to study these problems. 
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